Some successes have been recorded also with CAR-CD19 in refractory chronic lymphoid leukemia (CLL) patients [8,13], whereas larger studies on CAR-CD19 are needed in non-Hodgkin lymphoma [17,18,25,38] with some preliminary encouraging results using CAR-CD20 T-cells [39,40]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.